A Clinical Study to Evaluate the Effect of Musli Sufaid in Men with Low Sperm Count

Evaluation of the Efficacy of Musli Sufaid (Chlorophytum arundinaceum Baker) in the Management of Oligozoospermia (Qillate Haiwane Manawia): An Open Label Single Arm Clinical Trial. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106174

Enrollment

Registered

2026-03-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N461- Oligospermia

Interventions

Intervention1: MUSLI SUFAID: 3 GRAMS SUFOOF ORALLY TWICE DAILY WITH PLAIN WATER FOR 90 DAYS Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male Patients between the age group 18-60 years. 2. Patient having sperm count more than 5 million/ml and less than 16 million/ml. 3. Sperm motility less than 40% 4. Patients those who will give written consent. 5. Patients ready to discontinue ongoing treatment, if any. 6. Patient underwent at least 2-week washout period before intervention.

Exclusion criteria

Exclusion criteria: 1. Patients below 18 years and over 60 years of age. 2. Patients having azoospermia on laboratory diagnosis. 3. Patients of known cases of genetic abnormalities like Klinefelter s Syndrome. 4. Patients diagnosed with any Uro-genital infection. 5. Patients having prolonged exposure to heat or continuous friction. 6. Patients who are currently taking antidepressant medications. 7. Patients diagnosed with structural anomalies like Hydrocele, Varicocele, Carcinoma of testis, Undescended testis, Epispadias, Hypospadias. 8. Patient having a past history of mumps. 9. Patients having a history of trauma like Urethral injury/genital injury, acquired blockage in vas deferens & epididymis (infection/surgical), and testicular torsion. 10. Patient with history of uncontrolled Diabetes mellitus and Hypertension. 11. Patient with history of systemic disorders like Renal disease, Liver disease, and Cardiac disease(s). 12. Patient having history of any STDs, HIV and Hepatitis B infections.

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of Musli sufaid on sperm count in the management of Qillate Haiwane Manawia.Timepoint: 1. To evaluate the efficacy: Assessment of semen analysis and serum testosterone level at baseline and 90th day. 2. To evaluate safety: CBC,LFT and RFT at baseline and 90th day. 3. For exclusion(if needed): RBS, USG scrotum, semen culture and VDRL.	—

Secondary

Measure	Time frame
1. To evaluate the efficacy of Musli sufaid on other semen analysis parameters (volume & motility) 2. To assess the effect of Musli sufaid on serum testosterone level. 3. To evaluate the effects of Musli sufaid on the quality of life of patients with oligozoospermia.Timepoint: 1. To evaluate the efficacy: Assessment of semen analysis and serum testosterone level at baseline and 90th day. 2. Assessment of Quality of Life index at baseline and 90th day.	—

Measure

Time frame

1. To evaluate the efficacy of Musli sufaid on other semen analysis parameters (volume & motility) 2. To assess the effect of Musli sufaid on serum testosterone level. 3. To evaluate the effects of Musli sufaid on the quality of life of patients with oligozoospermia.Timepoint: 1. To evaluate the efficacy: Assessment of semen analysis and serum testosterone level at baseline and 90th day. 2. Assessment of Quality of Life index at baseline and 90th day.

—

Countries

India

Contacts

Public ContactDr MD SARFARAJ ALI KHAN

AYURVEDIC AND UNANI TIBBIA COLLEGE AND HOSPITAL

drkhannaseem.akhtarkhan@gmail.com9810815997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026